The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

Nvidia has been the hottest stock since the start of the AI revolution, and I see one particular healthcare business ...

We recently published a list of 10 Worst Booming Stocks to Buy According to Short Sellers. In this article, we are going to ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.89% of ...

Mirum Pharmaceuticals Inc (MIRM) stock saw a decline, ending the day at $38.96 which represents a decrease of $-0.39 or -0.99% from the prior close of $39.35. The stock opened at $39.46 and touched a ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares are moving lower Friday after the Committee for Medicinal Products for ...

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

Today, Benzinga's options scanner identified 12 options transactions for McKesson. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 58% being bullish and 25% ...

With a market capitalization of just $1.9 billion, Recursion still provides a potentially good entry point for investors, but that's only if there are good reasons to think that its strategy will pan ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...